Loading
A phase 3 trial of Patritumab deruxtecan, Capecitabine, Doxorubicin and Trastuzumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) is a phase 3 interventional study registered as NCT07060807 by Merck Sharp & Dohme LLC, with 1000 participants planned, started 2025-07-21 and due to reach its primary completion in 2033-07-14. Interventions recorded: Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin and Trastuzumab deruxtecan.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Patritumab deruxtecan, Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Doxorubicin, Merck & Co. (MSD), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Doxorubicin, Merck & Co. (MSD), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.